Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals has entered a strategic agreement with Roche Holdings to develop and commercialize zilebesiran, a treatment for hypertension currently in Phase 2 of development. Alnylam will receive an upfront cash payment of $310 million and is eligible for additional payments, including development milestone payments over the next few years, as well as regulatory and sales milestones, for a potential deal value of up to $2.8 billion. Alnylam and Roche will co-commercialize zilebesiran in the U.S., with Roche having exclusive rights to commercialize outside the U.S.
July 24, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals has entered into a potentially lucrative partnership with Roche Holdings to develop and commercialize zilebesiran. This could significantly boost Alnylam's revenues and profitability.
The partnership with Roche Holdings could lead to significant revenue growth for Alnylam Pharmaceuticals, especially considering the potential deal value of up to $2.8 billion. This is likely to have a positive impact on Alnylam's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings has entered into a strategic partnership with Alnylam Pharmaceuticals to develop and commercialize zilebesiran. This could strengthen Roche's product portfolio and increase its market share in the hypertension treatment market.
The partnership with Alnylam Pharmaceuticals could strengthen Roche's product portfolio and increase its market share in the hypertension treatment market. This is likely to have a positive impact on Roche's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100